Home Metabolism -Neuronal Signaling FAAH

FAAH

FAAH Products

  • All (11)
  • FAAH Inhibitors (11)
  • New FAAH Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2631 URB597 URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.
Mol Metab, 2022, 65:101597
Int J Nanomedicine, 2021, 16:3661-3678
Int J Mol Sci, 2021, 22(14)7711
S2377 Biochanin A Biochanin A (4-Methylgenistein), an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM.
Mol Neurobiol, 2022, 10.1007/s12035-021-02674-6
Front Oncol, 2021, 11:652008
J Med Virol, 2019, 91(8):1440-1447
S2666 PF-3845 PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2.
Elife, 2020, 9;9:e55211
Front Pharmacol, 2020, 11:266
Sci Rep, 2020, 10(1):15556
S0497 JNJ-42165279 JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively.
Cell Death Differ, 2022, 10.1038/s41418-022-01054-4
S2421 PF-04457845 PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. PF-04457845 covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily.
Front Chem, 2018, 6:441
S5329 FAAH-IN-2 FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH).
S6609 JZL195 JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively.
S3586 URB937 URB937 is an orally active and peripherally restricted FAAH inhibitor with IC50 of 26.8 nM and increases anandamide levels.
S2828 JNJ-1661010 JNJ-1661010 (Takeda-25) is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.
S5932 BIA 10-2474 BIA 10-2474 is a novel fatty acid amide hydrolase (FAAH) inhibitor, with a potent inhibitory effect upon FAAH and prolonged action in vivo.
S8052 LY-2183240 LY-2183240 is a potent, covalent inhibitor of the EC-degrading enzyme fatty acid amide hydrolase (FAAH). LY-2183240 disrupts the cellular uptake of the lipid endocannabinoid (EC) anandamide and promote analgesia in vivo. LY-2183240 is also an inhibitor of monoacylgylcerol lipase (MGL).
S2631 URB597 URB597 (KDS-4103) is a potent, orally bioavailable FAAH inhibitor with IC50 of 4.6 nM, with no activity on other cannabinoid-related targets. Phase 1.
Mol Metab, 2022, 65:101597
Int J Nanomedicine, 2021, 16:3661-3678
Int J Mol Sci, 2021, 22(14)7711
S2377 Biochanin A Biochanin A (4-Methylgenistein), an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM.
Mol Neurobiol, 2022, 10.1007/s12035-021-02674-6
Front Oncol, 2021, 11:652008
J Med Virol, 2019, 91(8):1440-1447
S2666 PF-3845 PF-3845 is a potent, selective and irreversible FAAH inhibitor with Ki of 230 nM, showing negligible activity against FAAH2.
Elife, 2020, 9;9:e55211
Front Pharmacol, 2020, 11:266
Sci Rep, 2020, 10(1):15556
S0497 JNJ-42165279 JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively.
Cell Death Differ, 2022, 10.1038/s41418-022-01054-4
S2421 PF-04457845 PF-04457845 (PF-4457845) is a potent, favorable selective inhibitor of Fatty acid amide hydrolase (FAAH) with IC50 of 7.2 nM and 7.4 nM for hFAAH and rFAAH, respectively. PF-04457845 covalently modifies the active-site serine nucleophile of FAAH with exquisite selectivity relative to other members of the serine hydrolase superfamily.
Front Chem, 2018, 6:441
S5329 FAAH-IN-2 FAAH-IN-2 is an inhibitor of fatty acid amide hydrolase (FAAH).
S6609 JZL195 JZL195 is a potent inhibitor of both FAAH and MAGL with IC50s of 2 and 4 nM respectively.
S3586 URB937 URB937 is an orally active and peripherally restricted FAAH inhibitor with IC50 of 26.8 nM and increases anandamide levels.
S2828 JNJ-1661010 JNJ-1661010 (Takeda-25) is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.
S5932 BIA 10-2474 BIA 10-2474 is a novel fatty acid amide hydrolase (FAAH) inhibitor, with a potent inhibitory effect upon FAAH and prolonged action in vivo.
S8052 LY-2183240 LY-2183240 is a potent, covalent inhibitor of the EC-degrading enzyme fatty acid amide hydrolase (FAAH). LY-2183240 disrupts the cellular uptake of the lipid endocannabinoid (EC) anandamide and promote analgesia in vivo. LY-2183240 is also an inhibitor of monoacylgylcerol lipase (MGL).

Choose Selective FAAH Inhibitors

FAAHSignaling Pathway

FAAH信号通路图
Tags: FAAH inhibition | FAAH activity | FAAH assay | FAAH inhibitors clinical trials | FAAH inhibitor review